While the world has largely been focused on the development of vaccines and therapeutics for Covid-19, the U.S. Food and Drug Administration has remained busy lining up potential approvals of medications for other diseases and illnesses.

Shares of LogicBio plunged more than 25 percent after the company disclosed that the U.S. Food and Drug Administration placed a clinical hold on the proposed gene therapy treatment for methylmalonic acidemia (MMA).